Neuraxis, Inc. (NRXS)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $76.93M
Last updated: Nov 17, 2026 at 11:06 AM ET
Neuraxis, Inc. (NRXS) Earnings: Report Dates and Results
Neuraxis (NRXS) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Neuraxis reported EPS of -$0.52, below the -$0.21 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NRXS has an expected report date of Mar 17, 2027.
NRXS Earnings Call
The latest NRXS earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 12 quarters below that had an estimate, NRXS beat 3 and missed 9. Revenue for the quarter ended Sep 30, 2026 was $2.03M, up 150.2% from $811414 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.52 | -$0.21 | -$0.21 - -$0.21 | -147.62% | Miss | N/A | 1 | 0 up, 0 down | Nov 9, 2026 | $2.03M |
| Jun 30, 2026 | -$0.19 | -$0.32 | -$0.50 - -$0.14 | +40.63% | Beat | N/A | 2 | 0 up, 1 down | Aug 11, 2026 | $1.93M |
| Mar 31, 2026 | -$0.18 | -$0.24 | N/A | +25.75% | Beat | N/A | 2 | 1 up, 0 down | May 12, 2026 | $1.61M |
| Dec 31, 2025 | -$0.10 | -$0.21 | -$0.22 - -$0.17 | +52.38% | Beat | N/A | 2 | 0 up, 1 down | Mar 19, 2026 | $968127 |
| Sep 30, 2025 | -$0.24 | -$0.20 | -$0.24 - -$0.16 | -20.00% | Miss | N/A | 2 | 0 up, 1 down | Nov 10, 2025 | $811414 |
| Jun 30, 2025 | -$0.22 | -$0.19 | -$0.20 - -$0.18 | -15.79% | Miss | N/A | 2 | 1 up, 0 down | Aug 12, 2025 | $894086 |
| Mar 31, 2025 | -$0.33 | -$0.24 | -$0.24 - -$0.24 | -37.50% | Miss | N/A | 1 | 0 up, 0 down | May 12, 2025 | $895655 |
| Dec 31, 2024 | -$0.21 | $0.04 | N/A | -612.50% | Miss | N/A | N/A | N/A | Mar 20, 2025 | $761165 |
| Sep 30, 2024 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Nov 12, 2024 | $666625 |
| Jun 30, 2024 | -$0.42 | -$0.05 | N/A | -743.20% | Miss | N/A | N/A | 0 up, 0 down | Aug 9, 2024 | $611500 |
| Mar 31, 2024 | -$0.32 | -$0.10 | N/A | -220.00% | Miss | N/A | N/A | 0 up, 0 down | Apr 9, 2024 | $646635 |
| Dec 31, 2023 | -$0.25 | -$0.15 | N/A | -69.80% | Miss | N/A | N/A | 0 up, 0 down | Feb 28, 2024 | $531458 |
| Sep 30, 2023 | -$1.35 | -$0.17 | -$0.17 - -$0.17 | -694.12% | Miss | N/A | 1 | 0 up, 0 down | Nov 20, 2023 | $477460 |
| Jun 30, 2023 | -$1.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2023 | $646021 |
| Mar 31, 2023 | -$0.38 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 31, 2023 | $805110 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.89, after -$1.20 the year before. It was -$3.19 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.89 | N/A |
| Dec 31, 2024 | -$1.20 | N/A |
| Dec 31, 2023 | -$3.19 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,900 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 5,858 | 5 | |
| 2025Q4 | Dec 31, 2025 | 7,581 | 7 | |
| 2025Q3 | Sep 30, 2025 | 5,482 | 5 | |
| 2025Q2 | Jun 30, 2025 | 5,583 | 5 | |
| 2025Q1 | Mar 31, 2025 | 4,379 | 4 | |
| 2024Q4 | Dec 31, 2024 | 4,884 | 4 | |
| 2024Q3 | Sep 30, 2024 | 6,041 | 5 | |
| 2024Q2 | Jun 30, 2024 | 4,794 | 5 |
2026Q1 Earnings Call
Opening remarks
Behnam Shamsian Investor Relations Thank you, and good morning, everyone. Thank you for joining us for NeurAxis' First Quarter 26 Financial Results and Corporate Update Conference Call. Joining us on today's call is Brian Carrico, CEO of NeurAxis, and Timothy Henrichs, CFO of NeurAxis. At the conclusion of today's prepared remarks, we will open the call to questions. Please follow the operator's instructions to ask questions. Today's event is being recorded and will be available for replay through the webcast information provided in the press release. Finally, I would also like to call your attention to the customary safe harbor disclosures regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations, and future potential financial and operational results of NeurAxis. Although management believes these statements are reasonable based on estimates, assumptions, and projections as of today, these statements are not guarantees of future performance. Time-sensitive information may no longer be accurate at the time of any telephonic or webcast replay. Actual results may differ materially as a result of risks, uncertainties, and other factors, including, but not limited to, the factors set forth in the company's filings with the SEC. NeurAxis undertakes no obligation to update or revise any of these forward-looking statements. With that said, I would like to turn the event over to Brian Carrico.
Operator Operator Chief Executive Officer of NeurAxis. Brian, please proceed.
Brian Carrico Chief Executive Officer Thank you, Ben, and good morning to everyone joining us. Good to talk to everyone again. Quarter 26 was an important quarter for NeurAxis. I talked a little bit about this on the last earnings call 6 or 7 weeks ago. It was our first full quarter of operating with the Category 1 CPT code for PENFS, and it gave us the clearest view to date of what drives adoption, what continues to limit broader utilization, and where we need to focus our resources. I will structure my remarks today around six key areas. Number one, revenue and first quarter highlights; number two, insurance coverage status and payer progress; number three, key performance indicators or KPIs; number four, commercialization including our current structure, new hires and upcoming changes; number five, the VA opportunity; and number six, a summary of our focused next steps. Following my remarks, Timothy Robert Henrichs, our CFO, will review our financial results for the first quarter of 2026. For the first quarter 26, revenue was $1.6 million, compared with $896 thousand in Q1 2025, representing 80% year-over-year revenue growth. The quarter modestly exceeded our expectations, but the more important point is what we learned from the quarter.
Frequently Asked Questions About NRXS
When is Neuraxis's next earnings date?
Neuraxis's next earnings report is expected for Mar 17, 2027.
Did NRXS beat earnings estimates last quarter?
No. Neuraxis reported EPS of -$0.52 for the quarter ended Sep 30, 2026, below the -$0.21 estimate by 147.62%.
What EPS do analysts expect from NRXS next quarter?
The consensus EPS estimate for Neuraxis for the quarter ending Dec 31, 2026 is -$0.12 from 4 analysts, with estimates from -$0.18 to -$0.06.
How often does NRXS beat earnings estimates?
Neuraxis beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -89.33%.
NRXS pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts